Akoya Biosciences Inc

Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational and clinical research. The company was founded by Garry Nolan, Yury Goltsev and Nikolay Samusik in 2015 and is headquartered in Marlborough, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Akoya Biosciences achieves record revenue, eyes strategic growth initiatives

Akoya Biosciences reported impressive financial performance and outlined strategic priorities for 2023, focusing on revenue growth and operational enhancements.
While facing challenges like anemic reagent revenue and increasing expenses, the company remains optimistic about its position for growth and market opportunities.
With a strong emphasis on partnerships, product innovation, and revenue diversification, Akoya is poised to leverage its strengths and navigate challenges for sustained success.

Akoya Biosciences reports record Q1 revenue and eyes sustained growth

Akoya Biosciences' Q1 performance reflects strong revenue growth and strategic focus on sustained high growth.
The company aims for cash flow positivity by 2025 through targeted spending and revenue growth.
Challenges include successful Fusion 2.0 upgrades and driving reagent growth, balanced with maintaining high performance.
Opportunities lie in upgrading customers, partnerships, and innovative solutions driving revenue growth.

Akoya Biosciences reports record Q2 revenue and strategic growth plans

Akoya Biosciences excelled in Q2 2023 with record revenue and system placements, showcasing strength in spatial biology solutions.
The company's focus on reagent revenue growth, system upgrades, and revenue guidance highlights a strategic path for future growth.
While facing challenges in gross margins and adoption methodologies, Akoya's investments and opportunities position it well for continued success.

Akoya Biosciences excels in Q3, eyes sustained growth and efficiency

Akoya Biosciences delivered a standout performance in Q3 2023, marked by record revenue and gross profit, supported by a robust install base and strategic initiatives.
The company's strengths lie in workflow efficiency enhancements, strong gross margins, and a clear growth strategy through services and partnerships.
Challenges include achieving cash flow positivity, sustaining margins, and driving adoption of new solutions, while opportunities abound in genomics, partnerships, and market expansion.
Overall, Akoya's focus on innovation, efficiency, and market positioning sets a solid foundation for continued growth and financial success.

Akoya Biosciences reports record-breaking revenue and strategic partnerships for growth

Akoya Biosciences delivered impressive financial performance in Q4 2023, showcasing revenue growth, cost management, and strategic investments. While facing challenges from macro pressures and underperformance in certain regions, the company remains focused on achieving cash flow breakeven by 2024. Akoya's strengths in partnerships and product enhancements position them well for continued growth and margin expansion.

Akoya Biosciences reports Q1 revenue decline but eyes growth opportunities

Akoya Biosciences faced revenue decline in Q1 due to weak instrument placements but saw growth in reagent and services revenue, aiming for breakeven by year-end.
The company updated its 2024 revenue outlook, expecting a measured recovery and sustained growth, with opportunities in partnerships and margin improvement initiatives.
Challenges include academic budget assumptions impacting revenue guidance and increasing outsourcing to CROs affecting reagent growth opportunities.
Despite challenges, Akoya's strengths lie in strong reagent revenue growth, strategic partnerships, and potential for achieving higher gross margins in the future.

Akoya Biosciences reports strong Q2 revenue growth and eyes market expansion

Akoya Biosciences demonstrated robust revenue growth in Q2 2024, driven by strong performance across instrument, reagent, and service segments.
While facing challenges in revenue guidance adjustments and delayed impact from NMPA approval in China, Akoya's strategic initiatives and product strengths offer promising opportunities for future growth.
Overall, Akoya's focus on financial goals, product innovation, and market expansion sets a positive trajectory for the company's performance and competitiveness in the biotech sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Partnership aims to leverage spatial biology data, generated on Akoya's Phenoptics™ platform, to inform and guide drug development programs Partnership aims to leverage spatial biology data, generated on Akoya's Phenoptics™ platform, to inform and guide drug development programs

Akoya and AstraZeneca to Collaborate on Spatial Biology Approach to Profiling Tumor-Immune Biology

Company launches Advanced Biopharma Solutions (ABS), as the first pillar of the program, to enable spatial biomarker-guided drug development and clinical trials Company launches Advanced Biopharma Solutions (ABS), as the first pillar of the program, to enable spatial biomarker-guided drug development and clinical trials

Akoya Announces Rollout of Strategic Clinical Research Program to Advance Adoption of Spatial Biology for Clinical Applications

MARLBOROUGH, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2021.

Akoya Reports First Quarter 2021 Financial Results and Issues Full Year 2021 Guidance

The partnership brings together one of the world's premier microscopy vendors and Akoya's high-parameter CODEX® System for advancing the emerging field of spatial phenotyping and discovery The partnership brings together one of the world's premier microscopy vendors and Akoya's high-parameter CODEX® System for advancing the emerging field of spatial phenotyping and discovery

Akoya and ZEISS to Co-Market Innovative CODEX® Spatial Biology Workflow

MARLBOROUGH, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2021 after the market close on Tuesday, May 18, 2021. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Akoya to Report First Quarter 2021 Financial Results on May 18, 2021

Seeking researchers interested in pushing the boundaries of spatial biology and discovery through the CODEX® system's open, accessible interface Seeking researchers interested in pushing the boundaries of spatial biology and discovery through the CODEX® system's open, accessible interface

Akoya Biosciences Begins Accepting Applications for First-of-its-Kind Imaging Innovators (I²) Network

NEW YORK, May 3, 2021 /PRNewswire/ -- DLA Piper represented Akoya Biosciences, Inc. (Nasdaq: AKYA) in its recent initial public offering of 7,567,000 shares of its common stock at a price of $20 per share, including the exercise of the underwriters' option to purchase 987,000 shares of common stock, less underwriting discounts and commissions. Akoya offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response.

DLA Piper advises Akoya Biosciences in its US$151 million initial public offering

MARLBOROUGH, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the closing of its initial public offering of 7,567,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase 987,000 additional shares of common stock, at the initial public offering price of $20.00 per share. The gross proceeds to Akoya, before deducting underwriting discounts and commissions and offering expenses, were approximately $151.3 million. The shares began trading on The Nasdaq Global Select Market on April 16, 2021, under the symbol "AKYA."

Akoya Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

MARLBOROUGH, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the pricing of its initial public offering of 6,580,000 shares of its common stock at a price of $20.00 per share, for gross proceeds of $131.6 million, before underwriting discounts and commissions and offering expenses payable by Akoya. Akoya has also granted the underwriters a 30-day option to purchase up to an additional 987,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares are being offered and sold by Akoya. The shares are expected to begin trading on the Nasdaq Global Select Market on April 16, 2021 under the ticker symbol “AKYA.” The offering is expected to close on April 20, 2021, subject to the satisfaction of customary closing conditions.

Akoya Biosciences Announces Pricing of Initial Public Offering

News for Akoya Biosciences Inc Stock (AKYA)